Extended immunophenotype of CD3+/CD56+ T cells in AML compared with healthy donors
| . | AML, n = 36 % (± SD) . | Healthy, n = 17, % (± SD) . | P . |
|---|---|---|---|
| Effector CD45RAhigh/CD27− | 42.1 (13.2) | 11.7 (5.9) | .02 |
| Naive CD45RAhigh/CD27+ | 7.5 (3.5) | 27.3 (9.7) | .01 |
| Memory CD45RAlow/CD27+ | 10.7 (2.9) | 24.1 (11.2) | .04 |
| CD57+ | 63.1 (12.6) | 31.7 (11.9) | .04 |
| CD28+ | 45.4 (20.4) | 84.4 (8.8) | .04 |
| CD25+/CD69+ | 21.4 (22.3) | 2.2 (0.9) | .001 |
| . | AML, n = 36 % (± SD) . | Healthy, n = 17, % (± SD) . | P . |
|---|---|---|---|
| Effector CD45RAhigh/CD27− | 42.1 (13.2) | 11.7 (5.9) | .02 |
| Naive CD45RAhigh/CD27+ | 7.5 (3.5) | 27.3 (9.7) | .01 |
| Memory CD45RAlow/CD27+ | 10.7 (2.9) | 24.1 (11.2) | .04 |
| CD57+ | 63.1 (12.6) | 31.7 (11.9) | .04 |
| CD28+ | 45.4 (20.4) | 84.4 (8.8) | .04 |
| CD25+/CD69+ | 21.4 (22.3) | 2.2 (0.9) | .001 |
AML indicates acute myeloid leukamia; and SD, standard deviation.